- 期刊
- OpenAccess
Consequences of Different Corticosteroids on Serum Potassium and Prostate-Specific Antigen in Patients Receiving Abiraterone for Castration-Resistant Prostate Cancer: A Retrospective Observational Study
摘要
Background: Abiraterone acetate is an androgen synthesis inhibitor approved for the treatment of castration-resistant prostate cancer (CRPC). Although co-administration of either prednisone or prednisolone at 10 mg/d has been recommended to reduce the risk of abiraterone- induced hyperaldosteronism (notably hypokalemia) and to give adjunctive pain relief effects, whether these glucocorticoids can be substituted by dexamethasone remains unknown. Methods: We performed a retrospective review of medical records of patients who were given abiraterone for the treatment of CRPC with either prednisolone (ABI/PSL) 10 mg/d or dexamethasone (ABI/DEX) 0.5 or 1 mg/d between 2014 and 2017 in Juntendo University Nerima Hospital. Demographic and biochemical data including prostate-specific antigen (PSA) level were retrieved from the electronic medical records. Results: Fifty-three eligible patients (27 in ABI/PSL group and 26 in ABI/DEX group) were extracted from the records. Both groups showed no significant changes in serum potassium level before and after starting treatment. In the ABI/PSL group, 12 patients (46%) showed elevations of PSA and 7 patients (27%) discontinued treatment within 3 months. In contrast, in the ABI/DEX group, only 6 patients (25%) showed elevations of PSA and 3 patients (13%, all were given dexamethasone 1 mg/d) discontinued treatment. Conclusions: Dexamethasone and prednisolone may be equally effective in preventing abiraterone-induced hypokalemia.
延伸閱讀
- A.Wall, B., Galvão, D. A., Fatehee, N., Taaffe, D. R., Spry, N., Joseph, D., & Newton, R. U. (2015). Reduced Cardiovascular Capacity and Resting Metabolic Rate in Men with Prostate Cancer Undergoing Androgen Deprivation: A Comprehensive Cross-Sectional Investigation. Advances in Urology, 2015(), 210-216. https://doi.org/10.1155/2015/976235
- 謝峽浪（2011）。Is Transurethral Resection of Prostate (TURP) Lowering the Risk of Prostatic Cancer for Patients with Benign Prostatic Hyperplasia：A Retrospective Cohort Study〔碩士論文，長榮大學〕。華藝線上圖書館。https://doi.org/10.6833/CJCU.2011.00235
- Woolen, S., Holzmeyer, C., Nesbitt, E., & Siami, P. F. (2014). Long-Term Efficacy and Tolerability of Abdominal Once-Yearly Histrelin Acetate Subcutaneous Implants in Patients with Advanced Prostate Cancer. Prostate Cancer, (2014), 103-107. https://doi.org/10.1155/2014/490315
- Martin, N. E., Chen, M. H., Beard, C. J., Nguyen, P. L., Loffredo, M. J., Renshaw, A. A., Kantoff, P. W., & D'Amico, A. V. (2014). Natural History of Untreated Prostate Specific Antigen Radiorecurrent Prostate Cancer in Men with Favorable Prognostic Indicators. Prostate Cancer, (2014), 149-154. https://doi.org/10.1155/2014/912943
- 陳敬倫（2016）。Identifications of anti-oncogenesis effects of statin related drugs on prostate cancer through gene expression profiling and population-based cohort studies〔碩士論文，臺北醫學大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0007-1407201615452100